Patents by Inventor Simon Robert Everitt

Simon Robert Everitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS
    Publication number: 20250353834
    Abstract: Provided in this application is a process for making Compound I (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels. Processes for making various intermediate products, and suitable salts thereof, are also provided.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 20, 2025
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Cristian HARRISON, Christopher John DAVIS, Simon Robert Everitt, Enrico EMER, Michael Edward O'Donnell, Stephen SHANAHAN, Mireia Sidera PORTELA, Bruno Artur SOUSA, Shujauddin M. CHANGI, Berenice L. LEWANDOWSKI, Maninder PANESAR, Andrew MCTIERNAN, Tharanga K. WIJETHUNGA
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 8841450
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell, Simon Robert Everitt